Clinical Study
The Use of Strontium-90 Beta Radiotherapy as Adjuvant Treatment for Conjunctival Melanoma
Table 1
Clinical data of participating patients.
| Patient | Age | Gender | Tumor location | Tumor size (mm) | Tumor thickness (mm) | TNM Classification1 | Primary excision and cryotherapy | Mode of strontium treatment | Time to strontium treatment (months) | Type of applicator
|
| 1 | 58 | F | Inferior temporal | 5 × 3 | 0.6 | T1N0MX | Y | Adjuvant (base and lateral) | 3 | SIA 6 | 2 | 86 | F | Temporal | 8 × 4 | 1 | T2N0MX | Y | Adjuvant (base and lateral) | 2 | SIA 6 | 3 | 72 | M | Inferior temporal | 5 × 5 | 1 | T4N0MX | Y | Base adjuvant | 3 | SIA 6 | 4 | 71 | M | Inferior nasal | 10 × 7 | 6 | T1N0MX | Y | Adjuvant (base and lateral) | 3 | SIA 6 | 5 | 92 | F | Temporal | 6 × 4 | 2.5 | T2N0MX | Y | Adjuvant (base and lateral) | 3 | SIA 6 | 6 | 72 | M | Temporal | 0.7 × 0.3 | Not assessed thoroughly | T4N0MX | Y | Secondary to recurrence | 4 | SIA 6 | 7 | 63 | F | Temporal | 6 × 4 | 0.6 mm | T2N0MX | Y | Adjuvant (base and lateral) | 2 | SIA 6 | 8 | 69 | M | Superior nasal | 3 × 1.8 | 1.9 | T1N0MX | Y | Adjuvant (base and lateral) | 3 | SIA 6 | 9 | 61 | F | Temporal | 2 × 2 | 4 | T1N0MX | Y | Adjuvant (base and lateral) | 3 | SIA 6 | 10 | 68 | F | Temporal | 9 × 3 | 1 mm | T2N0MX | Y | Secondary to recurrence | 4 | SIA 6 | 11 | 68 | M | Temporal | 14 × 8 | 3 | T2N0MX | Y | Adjuvant (base and lateral) | 1 | SIA 1 | 12 | 76 | M | Inferior temporal | 11 × 4.5 | 6 | T2N0MX | Y | Adjuvant (base and lateral) | 2 | SIA 6 | 13 | 65 | F | Temporal | 10 × 8 | 1.3 | T2N0MX | Y | Adjuvant (base and lateral) | 3 | SIA 6 | 14 | 60 | M | Nasal | 7 × 5 | 2 | T2N0MX | Y | Secondary to recurrence | 3 | SIA 1 | 15 | 69 | M | Temporal | 13 × 6 | 1.5 | T2N0MX | Y | Adjuvant (base and lateral) | 1 | SIA 1 | 16 | 67 | M | Superonasal | 6 × 1 | 1 | T1N0MX | Y | Secondary to recurrence | 1 | SIA 6 | 17 | 63 | F | Temporal | 7 × 2.5 | 1 | T2N0MX | Y | Adjuvant (base and lateral) | 2 | SIA 6 | 18 | 54 | F | Temporal | 6 × 3 | 1 | T2N0MX | Y | Adjuvant (base and lateral) | 1 | SIA 6 | 19 | 69 | F | Superior | N/A | N/A | T1N0MX | Y | Adjuvant (base and lateral) | 2 | SIA 6 | 20 | 72 | M | Superior | 1.5 × 1.0 | Not assessed thoroughly | T1N0MX | Y | Adjuvant (base and lateral) | 4 | SIA 6 |
|
|
TNM classification primary tumour (T): TX: primary tumour cannot be assessed, T0: no evidence of primary tumour, T1: tumour of bulbar conjunctival occupying one quadrant or less, T2: tumour of the bulbar conjunctiva occupying more than 1 quadrant, T3: tumour of conjunctival fornix and palpebral conjunctiva or caruncle, T4: tumour invades eyelid, cornea, or orbit. Regional lymph nodes (N): N: NX: regional lymph nodes cannot be assessed, N0: no regional lymph node metastasis, N1: regional lymph node metastasis. Distant metastasis (M): MX: distant metastasis cannot be assessed, M0: no distant metastasis, M1: distant metastasis.
*SIA 6: 12 mm ophthalmic applicator, SIA 1: 18 mm ophthalmic applicator.
|